Boston, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is reshaping one of healthcare's most consequential clinical domains — intravenous therapy and vascular access — as mounting pressure to eliminate medication errors, automate hospital workflows, and extend care beyond traditional settings accelerates investment in AI-enabled infusion technologies. BCC Research's latest intelligence offering, AI Impact on Intravenous (IV) Therapy and Vein Access Market — BCC Pulse Report, examines how AI adoption, digital health funding momentum, and emerging connected-care platforms are converging to redefine the clinical and commercial landscape for IV therapy and vein access.
Key Findings
• Broad AI investment is providing foundational capital: Private U.S. AI investment reached $109.1 billion in 2024 — more than eleven times China's $9.3 billion and more than twenty-four times the U.K.'s $4.5 billion, according to the Stanford AI Index Report 2025. Generative AI alone attracted $33.9 billion globally in 2024, up 18.7% year-over-year, signaling sustained institutional confidence in AI-driven healthcare applications.
• Digital health funding reflects early-stage pipeline strength: U.S. digital health funding reached $10.1 billion across 497 deals in 2024, with 63% of rounds concentrated at Seed, Series A, or Series B stages — indicating a robust and maturing pipeline of emerging AI-enabled solutions, including those targeting IV therapy and vein access workflows.
• Medication safety and infusion error reduction are the primary adoption catalysts: Growing concerns over incorrect dosing, high-alert medication mismanagement, and infusion-related adverse events are compelling healthcare providers to integrate AI-enabled infusion technologies capable of analyzing medication orders, patient data, and real-time pump parameters to generate pre-administration and mid-administration alerts.
• Intelligent infusion pumps and connected care platforms are the leading commercial vehicles: Modern smart pump platforms — combining drug libraries, dose-error reduction software, barcode verification, and cloud connectivity — are the dominant AI deployment pathway. BD's October 2025 launch of the BD Incada Connected Care Platform and Baxter's real-world data from over 1.3 million IV infusions across six hospitals using Spectrum IQ smart pumps integrated with EMRs exemplify the trajectory.
• Emerging technologies span the full care continuum: Key innovation categories include AI-Powered Smart Infusion Pumps, AI-Enabled Ultrasound-Guided Vascular Access, AI-Powered Robotic Ultrasound for Central Venous Catheterization, AI-Based Clinical Decision Support for Parenteral Nutrition (TPN2.0), Connected Infusion Care Platforms and EMR Interoperability, and AI-Driven Predictive Analytics and Workflow Automation.
• Major industry players are committing significant capital: Key companies active in this space include B. Braun, BD (Becton, Dickinson and Company), Baxter, Terumo Corporation, FUJIFILM Sonosite, Siemens Healthineers, and Veinsound.
Strategic Implications
The structural forces driving AI adoption in IV therapy are both clinical and operational. On the clinical side, medication error prevention and dosing accuracy represent non-negotiable safety imperatives, particularly for high-alert IV medications and complex regimens such as total parenteral nutrition, where manual prescription errors in high-risk populations including neonates can result in life-threatening complications. AI's ability to cross-reference patient data, flag inconsistencies, and integrate with pharmacy and EMR systems positions it as a critical layer of patient safety infrastructure.
On the operational side, nursing workforce pressures, rising healthcare costs, and the accelerating shift toward home-based care and remote patient monitoring are creating systemic demand for AI-driven automation. Connected infusion platforms that enable centralized monitoring, predictive maintenance, and real-time deviation alerts are increasingly viewed not as premium features but as baseline requirements for scalable, cost-efficient care delivery. Government-led digital health programs across Asia-Pacific and global frameworks such as the WHO Global Strategy on Digital Health are further accelerating institutional adoption by providing regulatory clarity and infrastructure investment, particularly in emerging markets where Terumo Corporation is actively advancing AI-driven digital transformation initiatives.
Investment Considerations
For investors evaluating exposure to this space, the opportunity is substantial but layered with important nuances. Established medtech incumbents — particularly B. Braun, which committed over $1.60 billion (€1.4 billion) to R&D, production expansion, and digital technologies in 2025, and BD, which is actively expanding its Connected Care ecosystem — are best positioned to capture near-term revenue from hospital system upgrades. Baxter's continued investment in its Spectrum IQ and Novum IQ platforms, including Dose IQ analytics and expanded cloud interoperability, reinforces the trend toward platform-level competition. Meanwhile, FUJIFILM Sonosite's 2025 launch of PIV Assist — an AI-powered ultrasound function offering real-time vein recognition and color-coded vascular guidance — highlights the adjacent vascular access opportunity. Key risks include cybersecurity vulnerabilities inherent to connected infusion devices, the persistent requirement for human clinical oversight that constrains full automation, and the relative scarcity of venture capital funding explicitly targeting IV AI applications, which may slow the pace of dedicated early-stage innovation compared to broader digital health categories.
About the Report
AI Impact on Intravenous (IV) Therapy and Vein Access Market — BCC Pulse Report provides qualitative strategic intelligence on AI adoption trends, emerging technologies, investment dynamics, competitive activity, and key drivers and challenges shaping the IV therapy and vein access landscape across clinical and commercial dimensions.
About BCC Research
BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth trends, identify and evaluate new and changing market opportunities, and provide critical information and innovative decision support tools to help inform the strategic decision-making process.
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
BCC Research LLC 50 Milk St., Ste. 16, Boston, MA 02109 press@bccresearch.com | +1 781-489-7301 www.bccresearch.com
